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Abstract
Background: The development and simulation of dynamic models of terpenoid biosynthesis has yielded a systems
perspective that provides new insights into how the structure of this biochemical pathway affects compound
synthesis. These insights may eventually help identify reactions that could be experimentally manipulated to
amplify terpenoid production. In this study, a dynamic model of the terpenoid biosynthesis pathway was
constructed based on the Hybrid Functional Petri Net (HFPN) technique. This technique is a fusion of three other
extended Petri net techniques, namely Hybrid Petri Net (HPN), Dynamic Petri Net (HDN) and Functional Petri Net
(FPN).
Results: The biological data needed to construct the terpenoid metabolic model were gathered from the literature
and from biological databases. These data were used as building blocks to create an HFPNe model and to
generate parameters that govern the global behaviour of the model. The dynamic model was simulated and
validated against known experimental data obtained from extensive literature searches. The model successfully
simulated metabolite concentration changes over time (pt) and the observations correlated with known data.
Interactions between the intermediates that affect the production of terpenes could be observed through the
introduction of inhibitors that established feedback loops within and crosstalk between the pathways.
Conclusions: Although this metabolic model is only preliminary, it will provide a platform for analysing various
high-throughput data, and it should lead to a more holistic understanding of terpenoid biosynthesis.
Background
Biological networks are complex and may consist of
hundreds of reactions that directly and indirectly affect
each other. In order to understand the relationship
between these reactions in detail, it is necessary to view
the network as a whole [1]. Computational models of
metabolic networks have been developed in order to
provide an overview of the biosynthetic processes
involved in multiple pathways [2,3]. Using such models,
changes in the concentration of each metabolite corre-
sponding to those that occur during normal and per-
turbed conditions can be simulated and used to
determine how such changes may contribute to the
entire biosynthetic process. The use of computational
models of this type gives researchers an in-depth view
of the problems that need to be solved and points to
new strategies and alternatives.
Various approaches can be taken to building and simu-
lating a biological pathway model [4]. The most popular
way of describing the behaviour of such a model is the
Ordinary Differential Equations (ODEs) approach [5-7].
ODEs are typically derived from the Michaelis-Menten
equation. They are then embedded into the model through
script writing using programs such as SimBiology in
Matlab [8] and Gepasi [9] that were developed for building
and editing such models. However, choosing the right
approach to building a particular biological model relies
on the type of biological pathway it is to represent. Typi-
cally, there are three categories of biological pathways:
gene regulatory networks [10,11], metabolic pathways
[6,12-14] and signalling pathways [4,7,15]. The model pre-
sented here, which describes the biosynthesis of terpenoids
via two independent pathways, one involving mevalonate
(MEV) and one involving methylerythritol phosphate
(MEP), falls into the metabolic pathways category.
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work using Hybrid Functional Petri net with extension
(HFPNe). This method allows easy modelling of com-
plex biological information using a graphical approach
and also allows various types of entities to be modelled
together. The technique is derived from the traditional
Petri net theory that was first described by Carl Adam
Petri in his 1962 PhD dissertation [16]. HFPNe is an
extension of the HFPN architecture with extended fea-
tures resulting from fusion of three extended Petri net
techniques, namely Hybrid Petri net (HPN), Dynamic
Petri net (HDN) and Functional Petri net (FPN) [17-20].
This technique is suitable for our modelling purposes
for several reasons: (a) it is capable of utilising primitive
types (Boolean and string); (b) it is able to treat more
than one value in an entity; and (c) it is capable of treat-
ing object type for complicated bioprocesses. Finally,
HFPNe introduces the new notion of a generic entity, as
well as processing and enhancing simulation processes
for this notion [17].
HFPNe-based biological models are built based on
three basic entities called places, transitions and arcs;
these are shown in Figure 1[21,22]. In addition to pos-
sessing the ability to model continuous and discrete
entities (places and transitions) concurrently as
described in HDNs, HFPNe introduces generic entities
that can hold values in the form of both real number
and Boolean strings. This feature enables on/off switches
and parameter modulators to be created, which can then
function as regulatory components in the model. These
HFPNe entities form a network and each is assigned
with specific parameters that describe its behaviour,
making this technique distinct from other Petri net
techniques [10,21-25]. The assignment of specific para-
meters to the HFPNe entities allows more options to be
customised in order to control the behaviour of the
model. The parameters of the entities and the topology
of their network are generated from biological facts that
can be obtained through experimental procedures and
by literature and database searches [10,23]. HFPNe and
other types of Petri net techniques allow an intuitive
approach to modelling; their ability to provide a visual
modelling framework for development and simulation
[13,14,21,25-29] motivated us to use this technique in
our modelling. HFPNe architecture has been success-
fully applied to the modelling of processes such as vulval
development [30] and the operation of microRNA regu-
latory networks [31] in Caenorhabditis elegans.
The biosynthesis of the universal precursors isopente-
nyl diphosphate (IPP) and dimethylallyl diphosphate
(DMAPP) occurs by two independent pathways, the
mevalonate (MEV) pathway and the methylerythritol
phosphate (MEP) pathway. These two pathways are dis-
tinct in terms of organism, cellular localisation and pro-
d u c t sa sw e l la si nt h em e t a b o l i t e sa n dp r e c u r s o r s
involved. The classical pathway, the MEV pathway, was
thought to be the only pathway involved in terpenoid
biosynthesis until the MEP pathway was discovered in
the early 90s [32,33]. The MEV pathway usually oper-
ates in the cytoplasm of eukaryotic organisms such as
Gallus gallus and Rattus norvegicus,w h e r e a st h eM E P
pathway takes place in the plastids of eubacteria such as
Escherichia coli and Streptomyces cerevisiae, as well as in
the chloroplasts of plants [34-36]. The MEP pathway is
not found in animals or fungi, making it attractive for
drug design studies because the enzymes in this pathway
are using a specific substrate or generate a specific pro-
duct and their function cannot be compensated for by
another enzyme [37,38]. However, both pathways are
operational in higher-level plants such as Arabidopsis
thaliana and Helianthus annuus, as well as in selected
eubacteria such as Streptomyces sp. [34,39-42].
Figure 1 HFPNe entities. Places, transitions and arcs are basic entities in the HFPNe architecture. Places and transitions can be subdivided into
continuous, discrete and generic.
Hawari and Mohamed-Hussein BMC Bioinformatics 2010, 11:83
http://www.biomedcentral.com/1471-2105/11/83
Page 2 of 11The several classes of terpenoids (e.g., monoterpenes,
sesquiterpenes, triterpenes and diterpenes) are organised
according to the number of isoprene units in their back-
bone. Isoprene units are five-carbon compounds that act
as the building block for terpenoids. Isoprenes (C5) con-
sist of one isoprene unit, monoterpenes (C10) consist of
two isoprene units, sesquiterpenes (C15) consist of three
isoprene units, diterpenes (C20) consist of four isoprene
units and the addition of more units will make up big-
ger terpene classes. The type of terpene produced also
depends on the route of biosynthesis. The MEV pathway
is more likely to produce sesqui- and triterpenes,
whereas the MEP pathway produces mono- and diter-
penes [34,37,43-45].
The topological network of the pathways in the model
was constructed based on reaction stoichiometry and
enzymatic mechanisms of known enzymatic reactions in
the terpene biosynthetic pathway. Underlying biological
information, including production and consumption
rates, was used to generate the parameters of each
HFPNe element that govern the behaviour of the model
during simulations. Simulation and validation processes
were then performed iteratively to produce an optimum
system.
In this study, the possibility of discovering new alter-
natives for amplifying the production of terpenoids was
the major goal. Therefore, a complete understanding of
how the compounds are synthesised is vital.
Results and Discussion
Model overview
This model consists of two subnetworks, the MEV and
MEP subnetworks, which represent the respective ter-
pene biosynthetic pathways. The study focuses on the
synthesis of two classes of terpenes, sesquiterpenoids
(the end product of the MEV pathway) and monoterpe-
noids (the end product of the MEP pathway). These two
pathways are placed in different compartments in
the model to reflect their different subcellular locations
(Figure 2). All of the metabolites involved in the
Figure 2 Overall sketch of the terpenoid biosynthetic pathways. The entire network is subdivided into MEV and MEP subnetworks, which
are placed in different compartments. A rough sketch of the network is shown in A, with the MEV subnetwork on the left and the MEP
subnetwork isolated in another compartment on the right. A clearer sketch of the MEV subnetwork is shown in B, and the MEP subnetwork is
shown in C. The identified enzymatic and crosstalk mechanisms are shown in the sketches.
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Page 3 of 11pathways are represented using HFPNe elements and
are interconnected to each other based on their reaction
stoichiometry and enzymatic mechanisms. The network
consists of 101 continuous transitions representing var-
ious reactions and production/degradation processes; 66
places representing 61 metabolites; three on/off
switches; and two parameter modulators. All metabolites
were represented using continuous places, whereas gen-
eric places were used to create the regulatory compo-
nents (on/off switches and parameter modulators). All
metabolites were represented using continuous places
whereas generic places were used to create the regula-
tory components (on/off switches and parameter modu-
lators) (Figure 3, see also Additional file 1).
The MEV subnetwork consists of ten main enzymatic
reactions and two feedback loops, whereas the MEP
subnetwork consists of nine main enzymatic reactions
and a crosstalk mechanism that also involves the MEV
subnetwork. The 19 main enzymatic reactions partici-
pating in both subnetworks are shown in Tables 1 and 2
and Figure 4. The behaviour of each reaction in the
pathway is described using HFPNe element parameters
such as speed of transition formulae, initial place values
and threshold arc values [18,21,22,25]. To simulate the
behaviour of the model in normal and/or perturbed
conditions, the entities representing on/off switches are
adjusted. The initial values of these entities can be
manipulated to create different conditions during the
simulation, leading to a better understanding of the
pathway and pointing to reactions to be further manipu-
lated. All simulations carried out in this study are based
on known information retrieved from literature and
database searches.
Based on the introduction of inhibitors and incre-
ments of metabolite concentration in both pathways,
together with the regulation of the three switch entities,
we here summarise five simulation conditions:
1) normal production of sesquiterpenes through the
MEV subnetwork, with the MEP subnetwork and all
inhibitory processes deactivated;
2) normal production of monoterpenes through the
MEP subnetwork, with the MEV subnetwork and all
inhibitory processes deactivated;
Figure 3 The overall layout of the terpenoid biosynthetic pathway model. All metabolites are represented using continous places whereas
the regulatory components such as the on/off switches and parameter modulators are represented using generic places. Each transition entity
represents a process such as phosphorylation, synthesis and degradation. Each substrate or intermediate is connected to the transition entity by
a normal arc whereas an enzyme is connected to its transition entity using a test arc. The MEV subnetwork is on the left and the MEP
subnetwork is secluded in a different compartment to depict that the pathway is operative in plastids of eubacterias or chloroplasts or plants.
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Page 4 of 113) overexpression of ATP in the fifth reaction of the
MEV subnetwork, with the MEP subnetwork and
other inhibitory processes deactivated;
4) overproduction of FPP in the ninth reaction of
the MEV subnetwork, with the MEP subnetwork
and other inhibitory processes deactivated;
5) establishment of a crosstalk mechanism with the
MEP subnetwork activated but with the MEV sub-
network as well as other inhibitory processes
deactivated.
Simulation and Validation
The simulation and validation processes, as well as the
developmental stages of the model performed in this
study, were carried out using Cell Illustrator https://
cionline.hgc.jp. The model was validated against known
data and information obtained from extensive literature
and database searches. Simulation results are returned
as concentrations (unit) versus Petri net time (pt)
graphs. Here, we discuss three of the five simulated con-
ditions carried out in the study.
a. Overproduction of ATP
In the fifth reaction of the MEV pathway, phosphome-
valonate kinase (PMK; EC 2.7.4.2) catalyses the pro-
duction of mevalonate diphosphate (MEVPP) and ADP
from mevalonate-5-phosphate (MEVP) and ATP
(Table 1) [46-48]. This reaction acts in a bi bi (also
known as two-substrate/two-product) sequential enzy-
matic mechanism with respect to the two substrates;
MEVP first binds to the free enzyme, followed by
ATP; the enzyme then releases the main product and
finally ADP [46]. Studies have shown that high concen-
tration of ATP halts the production of MEVPP and
thus blocks the entire pathway from continuing to
synthesise other intermediates. ATP acts as a competi-
tive inhibitor, binding to both sites of the free enzyme
and forming a dead-end complex. This obstructs the
Table 1 Reactions involved in the MEV pathway (in order of occurrence)
Order
a Reaction Enzyme Main product
b
1 acetylcoA + acetylcoA ® acetoacetyl-coA + coA acetylcoA C-acyltransferase (EC 2.3.1.9) acetoacetyl-coA
2 acetoacetylcoA + acetylcoA + H2O ® HMGcoA + coA HMGcoA synthase (EC2.3.3.10) HMGcoA
3 HMGcoA + 2NADPH + 2H
+ ® mevalonate + coA + 2 NADP
+ HMGcoA reductase (EC 1.1.1.34) MEV
4 MEV + ATP ® MEVP + ADP mevalonate kinase (EC 2.7.1.36) MEVP
5 MEVP + ATP ® MEVPP + ADP phosphomevalonate kinase (EC 2.7.4.2) MEVPP
6 MEVPP + ATP ® IPP + PO3 +C O 2 + ADP MEVPP decarboxylase
(EC 4.1.1.33)
IPP
7 IPP eftrightarrow DMAPP IPP isomerase
(EC 5.3.3.2)
DMAPP
8 IPP + DMAPP ® GPP GPP synthase
(EC 2.5.1.1 atau EC 2.5.1.10)
GPP
9 IPP + GPP ® FPP FPP synthase
(EC 2.5.1.1 atau EC 2.5.1.10)
FPP
10 FPP ® sesquiterpenoid sesquiterpene synthase sesquiterpenes
a Order of occurrence in the MEV pathway
b Main product that serves as the substrate for the next reaction in the MEV pathway
Table 2 Reactions involved in the MEP pathway (in order of occurrence)
Order
a Reaction Enzyme Main product
b
A G3P + pyruvate ® DXP + CO2 DXP synthase (EC 2.2.1.7) DXP
B DXP + NADPH + H
+ ® MEP + NADP
+ deoxyxylulose phosphate reductoisomerase (DXR;
EC1.1.1.267)
MEP
C MEP + CTP ® CPP-ME + diphosphate MEP cytidyltransferase (EC 2.7.7.60) CPP-ME
D CPP-ME + ATP ® pCPP-ME + ADP CPP-ME kinase (EC 2.7.1.1480) pCPP-ME
E pCPP-ME ® CMP + MEcycPP MEcycPP synthase (EC4.6.1.12) MEcycPP
F MEcycPP + protein diol ® HMBPP + H2O + protein
disulfide
HMBPP synthase (EC 1.17.4.3) HMBPP
G HMBPP + NADPH + 2H
+ ® IPP + DMAPP + H2O + NADP
+ HMBPP reductase (EC 1.17.1.2) IPP dan
DMAPP
H IPP + DMAPP ® GPP GPP synthase (EC 2.5.1.10 atau EC 2.5.1.1) GPP
I GPP ® monoterpenoid monoterpene synthase monoterpenes
a Order of occurrence in the MEP pathway
b Main product that serves as the substrate for the next reaction in the MEP pathway
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Page 5 of 11binding of MEVP to the enzyme and impedes the
downstream reactions in the pathway. However, it was
also shown that by increasing the concentration of
MEVP, the inhibitory effects of ATP could be reversed.
Higher concentrations of MEVP inhibit the synthesis
of ATP, lowering the concentration of ATP to a man-
ageable level. This allows the synthesis of MEVPP, as
well as downstream reactions, to resume (Figure 5)
[46].
To simulate this mutually antagonist inhibitory feed-
back loop, the ‘MEV_switch’ component is set to ‘true’
and the other two switches are set to ‘false.’ The para-
meter that controls the production of ATP is adjusted
to a higher value of 30 unit/pt from 10 unit/pt, resulting
in overproduction of ATP by 3-fold and activates the
inhibitory arc. The threshold value for the inhibitory arc
that suppresses the production of ATP is set to 80 units
to allow the inhibitory effect to take place.
Figure 4 The MEV and MEP pathway constructed using Cell Illustrator. The pathways are numbered according to sequence, as shown in
Tables 1 and 2.
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The second feedback loop identified in the MEV path-
way is a positive feedback mechanism. It is initiated
when FPP levels become high enough to inhibit the cat-
alytic activity of mevalonate kinase (MK; EC2.7.1.36).
MK catalyses the fourth reaction in the MEV pathway,
phosphorylation of mevalonate to produce mevalonate-
5-phosphate (MEVP) (Table 1). The inhibitory activity
of FPP halts the phosphorylation of mevalonate, thus
slowing the downstream processes, including the pro-
duction of FPP itself [49,50]. This will return FPP con-
centration to its normal level, releasing its inhibitory
effect on MK (Figure 6).
To simulate this behaviour, the ‘MEV_switch’ com-
ponent is set to ‘true’ and the two other switches are
set to ‘false.’ No other inhibitory processes except the
Figure 5 Concentration (unit) changes in metabolites involved in the feedback loop mechanism over time (pt). Oscillations between the
concentrations describe how MEVPP production halts when high concentrations of ATP are present and resumes when the concentration of
MEVP increases.
Figure 6 Concentration (unit) changes in metabolites involved in the feedback loop mechanism caused by overproduction of FPP
over time (pt). The simulation successfully describes how high concentrations of FPP affect the production of MEVP. The oscillatory behaviour
also affects the production of sesquiterpenes.
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Page 7 of 11inhibitory arc connecting FPP to the catalytic activity
of MK are activated. The threshold value of the arc is
set to 10 units from a higher value of 100 units to
allow the inhibitory effect to take place. The simula-
tion result shows an oscillatory behaviour of the con-
centrations of sesquiterpene, FPP and MEVPP over
time (Figure 6).
c. Crosstalk
A crosstalk mechanism between the MEP and MEV
s u b n e t w o r k si se s t a b l i s h e dw ith the introduction of the
inhibitor fosmidomycin. This inhibitor suppresses the
catalytic activity of deoxyxylulose-5-phosphate
reductoisomerase (DXR; EC1.1.1.267). Suppression of
DXR activity reduces the rates of the downstream reac-
tions in the MEP pathway, affecting the production of
monoterpenes (Figure 7). However, the inhibition also
triggers a flux of precursors (IPP and DMAPP) from the
MEP pathway to the MEV pathway, resulting in
increased sesquiterpene concentration despite the inacti-
vation of the MEV pathway (Figure 8) [51]. This event
is described in the model by assigning function values
to the transition elements of the components that are
involved in this mechanism. These functions are then
regulated by a switch component called ‘crossSwitch.’
Figure 7 Concentration (unit) changes in metabolites affected by the crosstalk mechanism over time (pt).W h e nt h ec o n c e n t r a t i o no f
fosmidomycin increases over time, monoterpene production decelerates at 100 pt; however, a slight increase in sesquiterpene concentration is
observed.
Figure 8 Concentration (unit) changes in levels of the main precursors involved in the crosstalk mechanism between both pathways
over time (pt). IPP_2 and DMAPP_2 are precursors from the MEP subnetworks, whereas GPP and FPP serve as precursors in the MEV
subnetwork. The transfer of fluxes from IPP_2 and DMAPP_2 to the MEV subnetwork enables GPP and FPP to be synthesised and thus produce
sesquiterpenes.
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witch’ component is set to ‘false.’ The ‘MEP_switch’
component is set to ‘true’ while the ‘crossSwitch’ com-
ponent is given a script value. The script value enables
the activation of the ‘fosmidomycin’ component after
150 pt, thereby establishing the crosstalk mechanism.
The simulation result successfully described oscillatory
changes in the concentrations of the metabolites
involved over time.
Conclusion
The simulation and validation processes performed
using the model are consistent with known biological
information and data. The intuitive approach introduced
by the HFPNe technique enables intricate modelling
tasks to be viewed and solved in a graphical perspective.
The model serves as a tool for better understanding the
reactions involved in both pathways and how they affect
each other. Perturbations performed on the model pro-
vide insight into the effects of manipulation of a single
reaction on the whole network and thus should facili-
tate both industrial and biomedical terpenoid
bioengineering.
Methods
Information and data acquisition
The biological information and data needed to construct
this model included information on the substrates, pro-
ducts and enzymes involved in the MEV and MEP path-
ways, as well as detailed enzymatic reaction information
such as reaction stoichiometry and enzyme mechanisms.
Consumption and production rates were also taken into
consideration in developing the dynamic model. This
information was used to design the model layout and
parameter assignments for each of the HFPNe elements.
The data were obtained through the use of extensive lit-
erature and biological databases including KEGG,
BRENDA, ENZYME, IUBMB, MetaCyc and PATHWAY
DATABASE [23,52-56].
Model template design and parameter assignment
The HFPN elements (place, transition and arc) represent
the metabolites and processes that comprise the MEV
and MEP biosynthetic pathways. Continuous places
represent the substrates, products, inhibitors and
enzymes in both subnetworks, whereas continuous tran-
sitions represent biological processes such as catalysis,
phosphorylation and degradation. Generic places repre-
sent the on/off switches and parameter modulators. The
normal arcs then connect places (enzyme, substrate, pro-
duct) to transitions while inhibitory arcs connect inhibi-
tors to their prospective inhibited processes. All these
components were arranged according to the reaction
stoichiometry and enzymatic mechanism in their order of
occurrence in the respective pathways (Tables 1 and 2).
Each of the HFPNe elements possesses different attri-
butes that characterise its function in the model. Para-
meter values are assigned to each of these attributes to
control the behaviour of the model during simulation.
These values are generated based on the biological
information obtained and are translated into virtual con-
centration values (initial values of places), ordinary dif-
ferential equations (speed formulas of transitions),
numeric values (threshold of normal and inhibitory
arcs) and scripts (on/off switches) [10,18,22-25].
Iterative model development
The test-driven models were simulated and validated
against known data obtained through literature searches.
Simulations were carried out under five different condi-
tions as explained in the Results and Discussion section.
Simulation results were displayed as concentration
(unit) versus time (pt) graphs. Petri net time (pt) indi-
cates virtual Petri net time units that do not correspond
to real time; concentration also is given in general con-
centration units (unit) that do not specifically corre-
spond to actual concentration units such as mM and
μM. The changes in metabolite concentrations (unit)
over time predicted by each simulation were validated
against known biological data to identify gaps and
inconsistencies. Uncorrelated biological behaviours were
re-examined and previous developmental steps (topolo-
gical design and parameter assignment) were repeated.
The simulation process was then re-executed and revali-
dated against known biological information. The entire
process was carried out iteratively in order to rule out
inconsistencies and obtain an optimum system.
List of abbreviations
ADP: (adenosine diphosphate); ATP: (adenosine tripho-
sphate); DMAPP: (dimethylallyl diphosphate); DXR:
(deoxyxylulose-5-phosphate reductoisomerase); EC:
(enzyme commission); GPP: (geranyl diphosphate);
HDN: (Hybrid Dynamic Petri net); HFPNe: (Hybrid
Functional Petri net with extension); HPN: (Hybrid Petri
net); IPP: (isopentenyl diphosphate); FPN: (Functional
Petri net); FPP: (farnesyl diphosphate); pt: (Petri net
time); MEP: (methylerythritol-5-phosphate); MEV:
(mevalonate); MEVP: (mevalonate-5-phosphate);
MEVPP: (mevalonate diphosphate); MK: (mevalonate
kinase); ODE: (ordinary differential equation); PMK:
(phosphomevalonate kinase).
Additional file 1: Two simulation files to complement Figure 3.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
83-S1.ZIP]
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